Impact of methocarbamol on opioid use after primary ventral and inguinal hernia repair.
Am J Surg
; 226(6): 813-816, 2023 12.
Article
em En
| MEDLINE
| ID: mdl-37385858
BACKGROUND: Multimodal analgesia is now a mainstay of perioperative care. Our aim is to assess the impact of adding methocarbamol on opioid use for patients undergoing primary ventral (umbilical and epigastric) hernia repair (PVHR) and inguinal hernia repair (IHR). METHODS: Retrospective review of patients undergoing PVHR and IHR who received methocarbamol, propensity score matched in a 2:1 fashion to patients not receiving methocarbamol. RESULTS: Fifty-two PVHR patients receiving methocarbamol were matched to 104 control patients. Study patients were prescribed fewer opioids (55.8 vs 90.4%; p < 0.001) and received lower MME (20 vs 50; p < 0.001), with no difference in refills or rescue opioids. For IHR, study patients received fewer prescriptions (67.3 vs 87.5%; p < 0.001) and received lower MME (25 vs 40; p < 0.001), with no difference in rescue opioid (5.9 vs 0%; p = 0.374). CONCLUSIONS: Methocarbamol significantly reduced opioid prescribing in patients undergoing PVHR and IHR without increasing the risk of refill or rescue opioid.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Hérnia Inguinal
/
Metocarbamol
/
Transtornos Relacionados ao Uso de Opioides
Limite:
Humans
Idioma:
En
Revista:
Am J Surg
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Estados Unidos